CHANDLER, Ariz., May 27, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:MCHP) – Microchip Technology Incorporated, a leading provider of smart, connected, and secure embedded control solutions, today announced that the Company will present at the TD Cowen 53rd Annual Global Technology, Media, and Communications Conference on Wednesday, May 28, 2025 at 10:50 a.m. (Eastern Time). Presenting for the Company will be Mr. Richard Simoncic, Chief Operating Officer, and Mr. Eric Bjornholt, Senior Vice President and Chief Financi ...

Company Participation - SenesTech, Inc. will participate in a webcast fireside chat and host one-on-one meetings with investors at the Lytham Partners Spring 2025 Investor Conference on May 29, 2025 [1] - The webcast presentation is scheduled for 3:30 p.m. ET and will be accessible via the conference home page or directly through a provided link [2] - Management will engage in virtual one-on-one meetings throughout the event, with arrangements available through Lytham Partners [3] Company Overview - SenesTech is focused on improving global health by managing animal pest populations through fertility control solutions [4] - The company developed ContraPest, the only U.S. EPA-registered contraceptive for male and female rats, along with Evolve and Evolve Mouse, which are EPA-designated minimum risk contraceptives for rodents [4] - SenesTech aims to integrate its products into pest management programs to enhance effectiveness and promote humane, safe, and sustainable pest control [4]

LEXINGTON, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company” or “Rapid Micro”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, is pleased to welcome Dr. Dafni Bika to the Company’s Board of Directors (the “Board”). “We are extremely pleased to welcome Dr. Bika to our Board of Directors,” said Robert Spignesi, President and C ...

NEW YORK, May 27, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Bitfarms Ltd. ("Bitfarms Ltd." or the "Company") (NASDAQ: BITF) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Bitfarms Ltd. investors who were adversely affected by alleged securities fraud between March 21, 2023 and December 9, 2024. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/bitfarms-ltd-lawsuit-su ...

Core Viewpoint - A class action lawsuit has been filed against Bitfarms Ltd. for alleged deficiencies in internal controls over financial reporting, leading to misstatements in financial statements and a need for restatement [1][2]. Group 1: Allegations and Financial Misstatements - The complaint alleges that Bitfarms failed to disclose deficient internal controls over financial reporting, resulting in the incorrect categorization of proceeds from digital asset sales [2]. - Bitfarms misclassified cash flows from the sale of digital assets as operating activities instead of investing activities, leading to inaccuracies in financial statements [2]. - The company also overstated its ability to remediate material weaknesses in its internal controls, particularly regarding the classification of 2021 Warrants [2]. - On December 9, 2024, Bitfarms announced that its consolidated financial statements for fiscal years 2022 and 2023 contained material errors and would need to be restated [3]. - Following the announcement, Bitfarms' stock price fell by $0.13 per share, or 6.07%, closing at $2.01 per share on December 10, 2024 [3]. Group 2: Class Action Participation - Shareholders who wish to serve as lead plaintiffs in the class action must file their papers with the court by July 8, 2025 [4]. - Participation in the case is not required to be eligible for recovery; shareholders can remain absent class members if they choose [4]. Group 3: Company Background - Robbins LLP is a recognized leader in shareholder rights litigation, dedicated to helping shareholders recover losses and improve corporate governance since 2002 [5].

Core Viewpoint - A class action lawsuit has been filed against SoundHound AI, Inc. for failing to disclose material weaknesses in its internal controls over financial reporting, particularly related to corporate acquisitions [1][2]. Group 1: Allegations - The lawsuit alleges that SoundHound did not disclose material weaknesses in its internal controls, which impaired its ability to account for corporate acquisitions [2]. - It is claimed that the company overstated its remediation efforts regarding these internal control weaknesses [2]. - The reported goodwill following the Amelia Acquisition was inflated and would require correction due to these weaknesses [2]. - SoundHound is expected to incur additional time and costs to account for the SYNQ3 and Amelia Acquisitions [2]. - The weaknesses increased the risk of the company being unable to file certain financial reports with the SEC in a timely manner [2]. Group 2: Stock Impact - On March 4, 2025, SoundHound announced it would be unable to timely file its Annual Report for 2024, citing the complexity of accounting for the SYNQ3 and Amelia Acquisitions [3]. - Following this announcement, SoundHound's stock price fell by $0.61, or 5.86%, closing at $9.72 per share [3]. Group 3: Class Action Participation - Shareholders may be eligible to participate in the class action against SoundHound AI, Inc. and can contact Robbins LLP if they wish to serve as lead plaintiff [4]. - Shareholders do not need to participate in the case to be eligible for recovery and can remain absent class members if they choose [4]. Group 4: Company Background - Robbins LLP is a recognized leader in shareholder rights litigation, dedicated to helping shareholders recover losses and improve corporate governance since 2002 [5].

Financial Data and Key Metrics Changes - The company reported a cash loss per month of approximately $400,000, which is nearly half of what it was a year ago, indicating improved cost management [10][12] - Interest expenses decreased by $165,000 for the quarter due to note conversions as part of balance sheet cleanup efforts [19] - The company has maintained consistent income from operations in the range of $1,800,000 per quarter, with a slight uptick noted [21] Business Line Data and Key Metrics Changes - Oil production remained stable, with an uptick in oil revenue attributed to market price fluctuations, while gas revenues increased by $50,000 for the quarter due to higher gas prices [23] - Lease operating expenses (LOE) decreased to $683,000 per month in Q1, down from $700,000 to $750,000 in the previous year [19][33] - The company has approved 45 workovers, which are expected to significantly increase production once funding is secured [15] Market Data and Key Metrics Changes - The company hedged 70% of its oil production at $70 per barrel, which mitigates the impact of current market price fluctuations [11][23] - Gas prices have performed better than oil prices, leading to increased gas revenue [46] Company Strategy and Development Direction - The company is focused on reducing debt and improving its balance sheet by retiring senior debt and preferred shares [39][78] - There is a strategic emphasis on workovers to increase production in the near term, with plans for drilling in the longer term [39][78] - The company is exploring low-cost acquisitions to enhance its asset base amid low oil prices [40][78] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future, stating that the stock is undervalued and that they are positioned for significant growth in the coming quarters [41][78] - The management believes that oil prices will stabilize around $70 per barrel, despite current market forecasts suggesting lower prices [62][66] - The company is actively seeking gas opportunities, including unconventional gas and specialty gas, to enhance revenue streams [46] Other Important Information - The company has made significant progress in reducing general and administrative (G&A) costs, with a target of a million-dollar reduction over the year [25][71] - The company is not planning to purchase its own drilling rig but may consider acquiring workover rigs as market conditions allow [68][69] Q&A Session Summary Question: Can you give us some color on your gas operations and what you think the future in gas will be for the company? - Management noted that gas prices have been more favorable than oil prices, and they are exploring gas opportunities, including specialty gas like helium [46][47] Question: How was your relationship with Chevron? - The company reported an excellent relationship with Chevron, which is interested in increasing oil production from the company [52][53] Question: Will the entire deal with Encore close in June, or can it be done in pieces? - Management indicated that the deal is likely to close all at once, with a target date in late June or early July [56] Question: Can you explain how the hedging program operates and do you make any money off of it? - The hedging program involves swaps that lock in prices for 70% of production, providing a safety net against market fluctuations [58] Question: Can you give your thoughts on the oil and gas business in '25 and how do you feel about what's been going on worldwide? - Management believes the Permian has peaked but expects oil prices to stabilize around $70, with a focus on workovers and better drilling practices [62][66] Question: Do you see an opportunity for you guys on as far as the rig count going down where you'll be able to get rigs at a cheaper price? - Management indicated that while they do not plan to buy a drilling rig, they may consider acquiring workover rigs if market conditions are favorable [68][69] Question: How do you look at 2025, especially with the industry under pressure? - Management is focused on further reducing costs and leveraging acquisitions to maintain a lean operation while expanding growth opportunities [70][73]

Codexis (CDXS) Conference Call Summary - May 22, 2025 Company Overview - **Company**: Codexis (CDXS) - **Industry**: Biotechnology, specifically focusing on siRNA (small interfering RNA) technology and enzymatic synthesis for genomic medicines Key Points and Arguments Industry Trends - **Surge in Demand for siRNA Therapeutics**: There is a recognized increase in demand for siRNA therapeutics, with significant interest in innovative manufacturing solutions [5][6] - **Shift Towards Enzymatic Synthesis**: The industry is moving towards enzymatic synthesis methods, which are seen as necessary to meet the scalability and purity requirements for siRNA production [6][18] Codexis Technology and Developments - **Ecosynthesis Technology**: Codexis' Ecosynthesis platform is positioned as a timely solution to the limitations of traditional solid-phase chemistry, with advancements in scalability and cost-effectiveness [10][18] - **Validation from Industry Leaders**: Codexis received external validation from major oligonucleotide manufacturers, highlighting the effectiveness of its double-stranded RNA ligase [6][7] - **Machine Learning Tool**: A newly developed machine learning tool aids customers in optimizing RNA fragment designs, demonstrating superior performance in identifying effective solutions [12][41] Customer Engagement and Market Position - **Increased Customer Interest**: There has been a notable shift in customer engagement, with decision-makers in process development now actively exploring Codexis' enzymatic solutions [17][18] - **Growing Customer Base**: The number of substantive discussions with potential customers has increased significantly, from single digits to over 20 prospects [20] - **Innovation Lab Capacity**: Codexis aims to fill its Eco Innovation Lab capacity with multiple customers, focusing on a diverse range of products [35][36] Competitive Landscape - **Leadership in Enzymatic Technology**: Codexis is recognized as a leader in enzymatic technology for siRNA manufacturing, with expectations to maintain this position through continued advancements [21][18] Future Outlook - **Partnerships and Collaborations**: Codexis is on track to sign a GMP scale-up partnership and anticipates selling its Eco Innovation Labs capacity by year-end [20] - **Focus on Stereochemistry Control**: The ability to control stereochemistry in siRNA production is seen as a significant advantage, allowing for the development of more effective therapeutic candidates [31][52] Additional Important Insights - **Transition from Proof of Concept to Production**: Codexis is moving from demonstrating proof of concept to establishing a practical production platform, emphasizing the importance of cycle times in manufacturing [27][28] - **Impact of Stereochemistry on Efficacy**: The control of stereochemistry is crucial for ensuring the activity and effectiveness of siRNA therapeutics, with implications for both existing and new products [50][52] This summary encapsulates the key discussions and insights from the Codexis conference call, highlighting the company's strategic positioning within the biotechnology industry and its advancements in siRNA technology.

Company Overview - Kinross Gold is a senior gold mining company with a diverse portfolio of mines located in the United States, Brazil, Chile, Mauritania, and Canada, focusing on operational efficiency, cost control, and strategic asset optimization [2] Earnings Estimates - Over the last 60 days, four analysts have increased their earnings estimates for Kinross Gold for both the current year and the next year, indicating positive revision activity [3] - The Zacks Consensus Estimate for 2024 has risen to $1.04 from $0.77 just two months ago, while next year's estimate increased from $0.80 to $1.16 [3][4] Growth Projections - Current year EPS growth is projected at 52.94%, with next year expected to grow another 12.3% to $1.16 [4] Macro Environment - Gold prices are reaching record highs, driven by both short-term safe-haven demand and longer-term trends, with expectations that the Federal Reserve will act soon, leading to a weaker dollar and lower real yields, which are favorable for gold prices [5] Cost Structure - Kinross Gold's all-in sustaining costs (AISC) are trending toward the lower end of its peer group, positioning the company to benefit significantly from any increase in gold prices [6] - If gold prices remain above $2,300 per ounce, Kinross is expected to be not just profitable but highly profitable [6]

 Presentations by leading siRNA CDMOs, Bachem, Nitto Avecia, and ST Pharm, highlight performance and transferability of Codexis double-stranded RNA ligases Management to host conference call today at 8 am Eastern Time to discuss data REDWOOD CITY, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, presented data at the TIDES USA annual meeting in San Diego, California. Codexis’ ...